ASCO 2021 | Mechanisms and management of short- and long-term CAR-T toxicities
Jennifer Brudno
• 27 May 2021
Jennifer Brudno, MD, National Cancer Institute, Bethesda, MD, outlines the short and long-term toxicities of chimeric antigen receptor (CAR) T-cell therapy. Short-term toxicities include cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICAN), whereas long-term toxicities include B-cell aplasia, hypergammaglobulinemia, and graft versus host disease (GvHD). Additionally, Dr Brudno discusses managing CAR T-cell-related toxicities by utilizing universal grading systems and immunosuppressants such as tocilizumab for short-term toxicities as well as immunoglobulin replacement therapy for B-cell aplasia. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
